Frequently Asked Questions
The market is segmented based on , By Type (Intraocular Hypertension, Glaucoma), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
.
The Global Ocular Hypertension Treatment Market size was valued at USD 3.00 USD Billion in 2022.
The Global Ocular Hypertension Treatment Market is projected to grow at a CAGR of 3% during the forecast period of 2023 to 2030.
The major players operating in the market include Aerie Pharmaceuticals, Abbvie, Angelini Pharma, Chong Kun Dang pharmaceutical Corp, Laboratorios Sophia, Lee Pharma Ltd, Neurim Pharmaceuticals LTD, Nicox, Novartis AG, Ocular Therapeutix, Sylentis, Taejoon Pharm, Takeda Pharmaceutical Company Limited, Bausch Health Companies , Merck & Co. , Pfizer , Teva Pharmaceutical Industries .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Shypertension treatment, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
